An organ is a regulated service
Shape is the visible part. The real product is continuous function, reserve under stress, coordination with the body, and survival over time.
What must actually be replaced
Each organ combines many jobs. A technology can be clinically valuable by replacing only the life-limiting subset, but that boundary must be explicit.
| Organ | Service delivered | Hardest systems requirement |
|---|---|---|
| Kidney | Clear solutes, balance water and electrolytes, regulate pressure, make hormones | Continuous flow, millions of filtering units, vascular compatibility |
| Liver | Metabolize, detoxify, synthesize proteins, store fuel, secrete bile | Many cell types, zonation, dual blood supply, immense reserve |
| Heart | Pump variable flow for billions of cycles | Electromechanical synchrony, coronary perfusion, valves, fatigue |
| Lung | Exchange gases across a vast thin interface | Air-blood barrier, branching geometry, motion, infection exposure |
| Pancreas | Sense glucose and secrete hormones with minute-scale control | Immune protection, oxygenation, feedback precision |
Specify the job
A kidney regulates chemistry and pressure, not merely filtration. A liver synthesizes, detoxifies, stores, and signals. The replacement target must define both baseline output and reserve under stress.
What the record shows at this step
- Reported evidence
- Dialysis demonstrates that replacing a defined subset of renal function is clinically decisive even though it reproduces little of the organ.
- Measured by
- Function, reserve, regulation, duration
- Principal risk
- A specification written around the visible function silently omits the regulation and reserve that keep a patient stable under stress.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Function, reserve, regulation, duration
Choose the cells
Autologous cells reduce mismatch but take time. Donor-derived or pluripotent cells can scale, but add immune, differentiation, and tumor-safety questions.
What the record shows at this step
- Reported evidence
- Stem-cell-derived islet cells have restored regulated insulin secretion in trial participants, under systemic immunosuppression.
- Measured by
- Identity, purity, potency, genomic stability
- Principal risk
- Banked lines spread qualification cost across many products but concentrate genomic and tumour-safety risk in one starting material.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Identity, purity, potency, genomic stability
Build the architecture
Scaffolds, self-organizing organoids, decellularized matrices, and bioprinting provide different control over shape, cell placement, mechanics, and microscopic organization.
What the record shows at this step
- Reported evidence
- A patient-specific bioprinted ear was implanted in a human reconstructive study in 2022, in avascular, low-metabolic tissue.
- Measured by
- Cell density, geometry, mechanics, reproducibility
- Principal risk
- Geometry is the most visible and least binding achievement; a correct shape says nothing about supply or maturity.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Cell density, geometry, mechanics, reproducibility
Create circulation
Thick living tissue needs hierarchical vessels that connect rapidly to blood flow. Diffusion alone cannot support an organ-scale construct.
What the record shows at this step
- Reported evidence
- A 2025 study reported organoids developing organ-specific vascular cells alongside organ tissue rather than after it.
- Measured by
- Perfusion, vessel integrity, thrombosis, oxygen delivery
- Principal risk
- A channel that carries fluid is not a blood vessel; without an endothelium at the right shear it clots, leaks, or remodels away.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Perfusion, vessel integrity, thrombosis, oxygen delivery
Mature the function
A tissue that expresses the right markers may still behave like fetal or incomplete tissue. It must respond, secrete, filter, exchange, or contract under load.
What the record shows at this step
- Reported evidence
- Stem-cell-derived tissues widely retain fetal-like metabolism and structure in published characterisation.
- Measured by
- Organ output, reserve capacity, feedback control
- Principal risk
- Marker expression is an intermediate measure, and passing it can substitute for the harder evidence of function under load.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Organ output, reserve capacity, feedback control
Connect to the patient
Surgeons must join vessels, ducts, nerves, and mechanical interfaces while controlling leakage, clotting, rejection, and infection.
What the record shows at this step
- Reported evidence
- Gene-edited pig kidneys have been connected to living recipients, one supporting a patient without dialysis for 271 days.
- Measured by
- Engraftment, anastomosis, innervation, compatibility
- Principal risk
- Blood vessels are only one interface; ducts, airways, conduction, and endocrine feedback each have their own failure mode.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Engraftment, anastomosis, innervation, compatibility
Manufacture the therapy
Living products vary. Each batch needs rapid evidence of sterility, identity, potency, and safety before a narrow clinical window closes.
What the record shows at this step
- Reported evidence
- Regulators have published frameworks for regenerative medicine and printed devices, but potency assays for living constructs remain unsettled.
- Measured by
- Yield, release time, failure rate, traceability
- Principal risk
- A release test that cannot predict clinical function quickly, without destroying the implant, blocks every downstream cost reduction.
Evidence statements describe published studies, trials, or authorised products. Risk statements are editorial readings of what the step leaves unsolved.
Yield, release time, failure rate, traceability
A convincing tissue sample is not yet an organ. The missing system is often circulation, and the missing evidence is duration.
The centimetre problem
Cells can survive only a short distance from oxygen and nutrients. Scaling millimetre tissue into a centimetre-scale solid organ requires vessels that span large surgical connections down to capillary exchange.
A channel that carries fluid is not yet a blood vessel. It needs a compatible lining, correct flow and shear, barrier function, remodeling, and a route to every metabolically active region.
Why thickness, not shape, is the wall
Oxygen reaches roughly 100 to 200 µm from a capillary. A slab fed only from its surfaces therefore keeps a viable fraction that falls in inverse proportion to its thickness.
A construct is fully supplied only when channel spacing is at or below twice the penetration distance, roughly 0.30 mm at the selected value. That is a capillary-scale requirement, and it is why printing a large vessel does not solve perfusion.
Replacement is a portfolio, not a ladder
External support, machines, donor biology, animal organs, and manufactured tissue can coexist. The right endpoint is patient benefit, not maximum biological resemblance.
| Approach | Current boundary | What it replaces | What remains |
|---|---|---|---|
| Dialysis and external support | Routine | Replaces selected functions | Burden, access, incomplete physiology |
| Valves, pumps, total artificial heart | Approved for selected uses | Mechanical flow and pumping | Power, thrombosis, bleeding, infection |
| Engineered skin and cartilage | Clinical products | Thin or low-metabolic tissue repair | Integration, indication, delivered cost |
| Engineered hollow tissue | Small human studies | Reconstruction with host integration | Scale, durability, reproducible manufacture |
| Gene-edited pig organs | Early clinical trials | Whole-organ physiology | Immune injury, infection, durable survival |
| Organoids and tissue chips | Research and drug development | Human disease models and screening | Maturity, standardization, translation |
| Bioprinted solid organs | Preclinical | Spatially designed living tissue | Vascularization, scale, complete function |
Use physics where biology is optional
Pumps and filters can be standardized, tested, and replaced. They excel at narrow functions but struggle with blood contact, power, infection, and full biochemical regulation.
Borrow an already-built organ
A pig supplies mature architecture and perfusion. Gene editing and immunomodulation focus the problem on cross-species compatibility, pathogens, ethics, and durable survival.
Manufacture from cells and instructions
Patient-derived or banked cells could reduce rejection and create renewable supply. The price is a much harder manufacturing and maturation problem.
Who is building what
Five routes are being pursued by companies, hospitals, and public programmes with very different claims and very different clocks. Search the record, or filter by route.
eGenesisEGEN-2784 porcine kidneyMulti-gene-edited pig kidney
- Reported evidence
- Gene-edited pig kidneys have moved from decedent studies and single-patient access into formal clinical trials in living recipients.
- Announced next step
- Cohort trials with defined survival, rejection, and infection endpoints.
- Unresolved risk
- Chronic immune injury, infection surveillance, durable graft survival, and immunosuppression burden.
United Therapeutics / RevivicorUKidney, UHeart10-gene-edited porcine organs with designated-pathogen-free supply
- Reported evidence
- Porcine hearts and kidneys transplanted under expanded access and early trial protocols; one kidney supported a living recipient for 271 days.
- Announced next step
- Repeatable supply from qualified herds and controlled facilities.
- Unresolved risk
- Scale of pathogen-free production, consistency between animals, and long-term outcome evidence.
Vertex Pharmaceuticalszimislecel (VX-880)Stem-cell-derived islet cells for type 1 diabetes
- Reported evidence
- Trial participants have achieved insulin independence with immunosuppression, showing manufactured cells can restore a regulated endocrine function.
- Announced next step
- Immune-protected or gene-edited cells that avoid systemic immunosuppression.
- Unresolved risk
- Immune protection without suppression is unproven; long-term durability and tumour safety require years of follow-up.
Mass General BrighamClinical xenotransplant programmePig kidney as a bridge to human transplantation
- Reported evidence
- Reported a pig kidney supporting a living recipient without dialysis before subsequent human transplantation.
- Announced next step
- Defining xenografts as a bridge rather than only a permanent replacement.
- Unresolved risk
- A bridge indication changes the endpoint but not the underlying immune and infection problems.
Miromatrix (United Therapeutics)mirokidney, miroliverELAPDecellularised porcine scaffolds recellularised with human cells
- Reported evidence
- External liver assist has entered early human study, using a perfused construct outside the body first.
- Announced next step
- Implantable recellularised organs after external perfusion is established.
- Unresolved risk
- Complete recellularisation, endothelial integrity, thrombosis, and reproducible manufacture.
3DBio TherapeuticsAuriNovoPatient-specific bioprinted living ear implant
- Reported evidence
- A bioprinted construct from the patient's own cells was implanted in a human reconstructive study in 2022.
- Announced next step
- Additional cartilage and reconstructive indications.
- Unresolved risk
- Avascular cartilage is a forgiving case; it does not establish a route to a perfused solid organ.
Organovo / academic bioprintingTissue constructsExtrusion and light-based printing of living tissue
- Reported evidence
- Printed tissues function as research models; the FDA describes printing whole organs such as hearts and livers as early stage.
- Announced next step
- Perfusable constructs that survive at clinically relevant thickness.
- Unresolved risk
- Capillary-scale vascularisation, cell maturity, and sterile reproducible production at scale.
CarmatAeson total artificial heartBioprosthetic pulsatile total artificial heart
- Reported evidence
- Implanted in patients in Europe as a bridge to transplant, with regulated commercial use in defined indications.
- Announced next step
- Longer support duration and destination therapy.
- Unresolved risk
- Power, thrombosis, bleeding, infection, device durability, and cost of the support pathway.
Abbott / AbiomedHeartMate 3, ImpellaDurable and temporary circulatory support
- Reported evidence
- Ventricular assist devices are approved and routine for selected indications, with large outcome registries.
- Announced next step
- Lower adverse-event rates and less invasive interfaces.
- Unresolved risk
- Blood contact, driveline infection, and the fact that pumping is not full cardiac physiology.
Academic organoid programmesVascularised organoids, tissue chipsSelf-organising tissue with organ-specific vasculature
- Reported evidence
- A 2025 study reported organoids developing specialised vascular cells alongside organ tissue; NIH programmes fund tissue-chip standardisation.
- Announced next step
- Models with adult-like maturity and reproducibility across laboratories.
- Unresolved risk
- Fetal-like maturity, batch variability, and a long distance between a better model and an implantable organ.
OPTN / SRTRNational transplant recordWaiting-list and outcome surveillance
- Reported evidence
- Annual data reports quantify the gap between candidates and available organs, the demand any replacement technology must meet.
- Announced next step
- Comparable endpoints against which new supply routes are judged.
- Unresolved risk
- Registry outcomes describe human allografts; xenografts and engineered tissue need their own long clocks.
FDA regenerative medicine programmesRegulatory pathwayOversight of cell, tissue, and xenotransplant products
- Reported evidence
- Published frameworks for regenerative medicine, xenotransplantation, and 3D-printed medical devices.
- Announced next step
- Potency assays and release criteria matched to living, variable products.
- Unresolved risk
- Release testing must predict clinical function quickly without destroying a patient-specific implant.
Status is reproduced from the research record below. A trial in progress is not a result, an expanded-access case is not a trial, and naming a programme here does not imply that its stated endpoint will be met.
Three milestones, three different meanings
Reconstruction, a bridge to transplant, and permanent whole-organ replacement are different clinical claims. A milestone in one category cannot validate another.
The discovery chain
- 1980s-present
Mechanical support matures
Artificial valves, ventricular assist devices, dialysis, and total artificial hearts prove that useful function can be separated from biology.
- 2006
Engineered bladder study
Seven patients received autologous-cell constructs on biodegradable scaffolds, an important demonstration in a relatively forgiving hollow organ.
- 2010s
Organoids and tissue chips
Self-organizing tissues became practical models for development, disease, and drug response, well before whole-organ replacement.
- 2022
Bioprinted ear construct enters patients
A patient-specific living implant moved bioprinting into a human reconstructive study, but did not establish a solid internal organ.
- 2024-2026
Living-recipient xenotransplants
Gene-edited pig kidneys moved from decedent studies and one-off access into formal clinical trials.
- 2025
Organ-specific vessels in organoids
Researchers reported organoids that develop specialized vascular cells alongside organ tissue, a step toward more realistic maturation.
The frontier in 2025 and 2026
Vessels are becoming part of the tissue, not an afterthought
Organ-specific vasculature
A 2025 study reported organoids in which vascular and organ tissues develop together, producing specialized vessel features. The immediate value is better models; transplantation remains further away.
Organ-scale network design
Model-guided tools can generate and simulate large synthetic vascular trees before fabrication. This improves geometry and perfusion, but capillary integration and living remodeling remain unsolved.
Formal xenotransplant trials
Trials replace isolated exceptional cases with protocols, defined cohorts, surveillance, and comparable endpoints. This is how a dramatic operation becomes usable evidence.
Cost falls only when variability falls
There is no defensible historical per-organ cost curve yet. Products, endpoints, and accounting boundaries are too different. The useful question is which parts of the stack can become repeatable.
Research craft
Manual protocols, scarce experts, low yields, long culture, destructive testing, and bespoke surgery.
High variance, unknown delivered costPlatform manufacture
Banked starting cells, closed bioreactors, automated imaging, inline sensors, standard scaffolds, and predictive release assays.
More batches pass the first timeDistributed clinical supply
Validated hubs manufacture common components while surgical centers perform final preparation and implantation.
Cost moves from labor to reusable processWhat does one delivered graft cost?
No defensible per-organ cost series exists. This is a structural model of a living product, built to show which term dominates, not to price a therapy.
Manufacturing cost of one released graft
- Successful build
- $225k
- Cost of failed builds
- $675k
- Cell bank and qualification
- $60k
- Builds started per delivery
- 4.00
Excludes surgery, immunosuppression, hospitalisation, lifetime follow-up, cold-chain logistics, and the clinical-trial cost of establishing the product. It counts manufacturing only, so it is a floor rather than a delivered price.
Calculation & assumptions
Cost per delivered graft = (materials + facility rate × culture days + release testing) ÷ release pass rate + amortised cell-bank and qualification cost.
The pass-rate term is the reason variability, not materials, sets the price. At a 25% pass rate, four builds are started for every graft implanted, so three quarters of all facility time and material is charged to a product no patient receives. Move the release slider alone and watch the total move further than any other control.
What pushes cost down
Cell banks replace patient-by-patient starts
Well-characterized pluripotent or immune-engineered lines could spread qualification cost across many products.
Condition: immune safety and genomic stabilityClosed systems replace clean-room choreography
Automated bioreactors can control nutrients, gases, mechanical cues, and contamination with less manual handling.
Condition: sensors must predict final potencyModels reduce failed builds
Imaging and simulation can design flow networks, estimate oxygen transport, and identify weak regions before cells are committed.
Condition: model predictions must transfer to living tissueResearch products fund the learning curve
Organoids and tissue chips create nearer-term demand for disease models and drug screening while fabrication tools mature.
Condition: reproducibility across laboratoriesThe hard problems interact
Solving vessels changes immune exposure. Solving cell supply changes tumor risk. Solving scale changes quality control. Integration, not a single breakthrough, sets the pace.
Perfusion across scales
A printable large vessel is not a capillary bed. The network must branch across orders of magnitude, remain leak-free, avoid clotting, and connect to host circulation immediately.
Adult-level maturity
Many stem-cell-derived tissues retain fetal-like metabolism and structure. Marker expression is not equivalent to years of adult function under stress.
Immune compatibility
Autologous manufacture is slow and variable. Universal cells and pig organs can scale, but innate immunity, antibodies, coagulation, and chronic rejection remain active systems.
Whole-organ integration
Blood vessels are only one interface. Bile ducts, urinary drainage, airways, electrical conduction, endocrine feedback, and nerves may all matter.
Release testing
The product may be alive, changing, and patient-specific. A potency assay must predict clinical function quickly without destroying the implant.
Long evidence clocks
A graft can work for weeks yet fail from fibrosis, immune injury, infection, tumor growth, or fatigue years later. Durable evidence cannot be compressed completely.
There is more than one finish line
- Looks like the tissueCells and structure resemble the target organ.
- Performs one functionThe construct produces a measurable organ-specific output.
- Survives perfusionBlood flows without leakage, clotting, or tissue death.
- Integrates in a patientThe graft connects and functions without destructive rejection.
- Works under stressThe system has physiological reserve, not merely baseline output.
- Can be manufactured reliablyProduction, release testing, logistics, and cost support broad treatment.
An optimistic view, with conditions
Organ replacement becomes modular before it becomes complete
The likely route to abundance is a sequence of partial victories: better external support, living patches, temporary biological bridges, xenogeneic organs, and eventually manufactured organs assembled from validated modules.
Evidence replaces anecdotes
Kidney xenotransplant trials measure survival, rejection, infection, and patient experience. Organoids become more vascular, standardized, and useful for drug testing.
Hybrid organs find the clinic
Devices combine membranes, sensors, electronics, and living cells. Engineered patches and endocrine cell implants solve bounded functions before whole solid organs.
Architecture becomes programmable
Cell banks, organ-specific vessels, mature parenchyma, and closed manufacturing converge into implantable constructs with replaceable modules and measurable reserve.
View the analyst probability ranges
| Milestone | Date | Analyst probability |
|---|---|---|
| Ten or more xenotransplant recipients pass one year of graft function | 2030 | 35-55% |
| An immune-protected cell therapy works without systemic immunosuppression | 2032 | 25-40% |
| A kidney xenograft trial reports outcomes comparable to a marginal human allograft | 2035 | 15-30% |
| A perfused engineered tissue thicker than one centimetre survives implantation in a person | 2033 | 20-35% |
| An engineered organ module is approved for a bounded endocrine or metabolic function | 2035 | 25-45% |
| A bioprinted solid organ replaces the full function of a native kidney, liver, or heart | 2045 | 5-15% |
Editorial judgements conditional on the record above, not published forecasts, trial guidance, or statistical confidence intervals.
The decisive measurements
Function
Clearance, flow, secretion, contraction, gas exchange, reserve capacity
Survival
Perfused volume, cell viability, graft duration, infection-free time
Compatibility
Immune injury, thrombosis, inflammation, immunosuppression burden
Manufacturing
Yield, release time, failure rate, sterility, delivered cost
Sources and boundaries
This report separates approved support devices, limited clinical tissue engineering, investigational xenotransplantation, and preclinical organ fabrication. Dates describe published milestones, not forecasts. The outlook is an editorial synthesis and is explicitly conditional.
- Clinical product
- Authorized or routinely used for a defined indication.
- Investigational
- Used under research or special regulatory authorization.
- Preclinical
- Tested in laboratory or animal systems, not established in people.
- Whole-organ replacement
- Durable, integrated function across the organ's clinically important jobs.